Skip to content

Released Mar 11, 2025, before the open

10-K filed Mar 11, 2025, 70 days after period end · 0001785530-25-000008

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$20.40MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$20,348,000N/M
Operating Cash Flowderived-$14,252,000N/M
Free Cash Flowderived-$14,375,000N/M

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Net Income-$20.40M-$12.00M-$11.93M-$17.87M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR